Skip to main content

Search

Show all results for

Home

Person

Kristen Lorentz

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (9)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials

Jeffrey Alan Hubbell, Peter Frey, Hans Mattias Larsson, Priscilla Suhasna Maithili Briquez, Kristen Lorentz

Aprotinin is a broad-spectrum serine protease inhibitor used in the clinic as an anti-fibrinolytic agent in fibrin-based tissue sealants. However, upon re-exposure, some patients suffer from hypersensitivity immune reactions likely related to the bovine or ...

2017

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF(164)

Jeffrey Alan Hubbell, Veronica Sacchi, Mikaël Martino, Kristen Lorentz, Martin Ehrbar, Elena Groppa

Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene delivery failed to show efficacy. Major challenges include the need to precisely control in vivo distribution of growth factor dose and duration of expression. Re ...

National Academy of Sciences2014

Materials and protein engineering approaches for modulating immunity

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Stephane Kontos, Marie Ballester, Kristen Lorentz, Laura Jeanbart, Alizée Jéléna Grimm, David Scott Wilson, Kym Lorenz Brünggel

Amer Chemical Soc2014